Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

s.

On the plus side, future prospects for Gilenya look positive, as 90% of neurologists in the study reported they plan to prescribe Gilenya in the future.  "We view Gilenya's launch and future outlook in the multiple sclerosis space as very promising," said Jemma Lampkin, lead researcher on the study. "Gilenya's launch trajectory and penetration into our physician panel is encouraging.  In addition, payors have been very receptive to Gilenya thus far, which bodes well for the drug from a reimbursement standpoint."  According to ITG's interviews with pharmacy benefit managers at 10 managed care organizations, planned reimbursement restrictions for Gilenya will be similar to those required for other disease-modifying MS agents. Furthermore, the majority of interviewed managed care organizations already reimburse the drug.

Event Pulse: Launch of Gilenya  includes analysis of a targeted Internet survey of 75 neurologists, 10 in-depth telephone interviews with pharmacy directors at major managed care organizations, and proprietary longitudinal treatment data from a panel of 200 neurologists spanning 2005-2010. Conducted in November 2010, the report takes an in-depth look at how the launch of Gilenya will affect the multiple sclerosis market. In addition, Event Pulse: Launch of Gilenya  evaluates uptake and use of recently launched <
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 8 www.leebio.com , Lee Biosolutions, Inc,continues ... enzyme for,clinical diagnostic, pharmaceutical manufacturers and clinical researchers,worldwide ... Current research on this important ... inflammation to multiple sclerosis, diabetes,stroke and gastric cancer ...
... Dec. 8 Cell Therapeutics, Inc. (CTI),(Nasdaq ... follow-up data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line ... of Hematology (ASH) 50th Annual Meeting by,Morschhauser, ... progression-free,survival (PFS) following Zevalin consolidation therapy for ...
Cached Medicine Technology:Myeloperoxidase Research Expands 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5
(Date:4/24/2014)... April 24, 2014 ,Take me out to the ... and kale chips. The more likely culprits include French ... , Unfortunately for children who play youth baseball, eating ... to weight problems, according to researchers at Wake Forest ... online edition of Childhood Obesity , found that ...
(Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... that virtually eliminated bloodstream infections in hospital intensive-care units ... 10 percent, a new study suggests. Although prior research ... at hospitals using the checklist, the new study is ... "We knew that when we applied safety science ...
... the tight barrier that protects the brain from the bloodstream ... research team led by scientists from The University of Texas ... the Journal of Clinical Investigation . In experiments ... payloads to image tumors, treat tumors, or can potentially do ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Feb. ... arthritis, many of them minority patients, aren,t getting needed ... designed to slow progression of the deformities and disability ... early, expert guidelines say. "Both patients and ...
... S.C. More than 200 experts will gather at Clemson ... of play, and they already agree on one thing: Children ... of Play is attracting health professionals, educators, parents and park ... Value of Play, which led to the creation of the ...
... Reporter , TUESDAY, Feb. 1 (HealthDay News) -- Teenagers ... meningitis, a potentially deadly infection of the tissue around ... cough vaccines in light of recent outbreaks, according to ... of Pediatrics issues updated vaccination guidelines annually. Its new ...
... for Therapeutic Radiology and Oncology (ESTRO), the European Head ... Medical Oncology (ESMO) in collaboration with other European partners, ... the 3rd International Conference on innovative approaches In Head ... multidisciplinarity and innovation, this meeting will specifically cover the ...
Cached Medicine News:Health News:Safety checklist use yields 10 percent drop in hospital deaths 2Health News:Safety checklist use yields 10 percent drop in hospital deaths 3Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:Too Few Get Needed Rheumatoid Arthritis Drugs: Study 2Health News:Too Few Get Needed Rheumatoid Arthritis Drugs: Study 3Health News:Clemson conference attracts experts concerned about children's 'play deficit' 2Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3Health News:3rd international conference on innovative approaches in head and neck oncology 2
... The UrinQuick Urine Chemistry Analyzer is ... analysis of urine test strips. The UrinQuick ... for QuickVue UrinChek 10+ SG and QuickVue ... analyzes the urine test strips by reflectance ...
... a qualitative assay for rapid detection of Strep ... Strep A test excels at detection of Strep ... colonization samples. This CLIA Waived test uses a ... Strep A leaves little chance for misdiagnosis, minimizing ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
...
Medicine Products: